The Vanguard Group, Inc. has recently announced that it has increased stake in OncoCyte Corporation (NASDAQ:OCX) by 0.06%. After grabbing 4.31 million shares, the institutional investor is now in possession of 2500.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 3.64% having worth around $1.57 million.
OncoCyte Corporation (OCX) concluded trading on 03/15/23 at a closing price of $0.20, with 2.21 million shares of worth about $0.44 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -77.67% during that period and on Wednesday the price saw a loss of about -20.00%. Currently the company’s common shares owned by public are about 118.61M shares, out of which, 106.54M shares are available for trading.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 5 analysts are covering the OCX stock and their offered price forecasts bring an average price target of $0.83. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $1.40 and could fall to a lowest price of $0.40. However, touching the estimated high of $1.40 would mean a gain of 85.71% for the stock.
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 66 times over the past 12 months. They bought 20,252,963 shares in 59 of the transactions. In 7 selling transactions, insiders dumped 432,514 shares.
Vanguard Total Stock Market Index, Vanguard Extended Market Index Fu, and Fidelity Extended Market Index Fu are the top 3 mutual funds which are holding stakes in OncoCyte Corporation Vanguard Total Stock Market Index is currently holding 3.08 million shares of worth totaling $1.12 million. The company recently came buying 0.0 shares which brought its stake up to 2.60% of the company’s outstanding shares. Fidelity Extended Market Index Fu, after buying 0.6 million shares, have now control over 0.51% of the stake in the company. It holds 0.0 shares of worth $0.22 million.
However, the stock later moved at a day high price of 0.2657, or with a loss of -20.00%. Stock saw a price change of -45.95% in past 5 days and over the past one month there was a price change of -55.56%. Year-to-date (YTD), OCX shares are showing a performance of -37.68% which decreased to -82.61% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.24 but also hit the highest price of $1.68 during that period. The average intraday trading volume for OncoCyte Corporation shares is 327.07K. The stock is currently trading -46.12% below its 20-day simple moving average (SMA20), while that difference is down -49.50% for SMA50 and it goes to -70.27% lower than SMA200.
The Vanguard Group, Inc. acquired 4.31 million shares of OncoCyte Corporation having value of about $1.57 million. Data submitted at the U.S SEC by The Vanguard Group, Inc. revealed that the firm now holds 2500.0 shares in the company valued at close to $500.0, or have control over 0.06% stake in the company. OncoCyte Corporation (NASDAQ: OCX) currently have 118.61M outstanding shares and institutions hold larger chunk of about 59.70% of that. Holding of mutual funds in the company is about 5.02% while other institutional holders and individual stake holders have control over 57.22% and 43.26% of the stake respectively.
The stock has a current market capitalization of $25.60M and its 3Y-monthly beta is at 1.63. It has posted earnings per share of -$0.66 in the same period. It has Quick Ratio of 2.80 while making debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for OCX, volatility over the week remained 23.43% while standing at 13.51% over the month.
Analysts are in expectations that OncoCyte Corporation (OCX) stock would likely to be making an EPS of -$0.09 in the current quarter, while forecast for next quarter EPS is -$0.09 and it is -$0.32 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.12 which is -$0.07 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.12 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -57.70% while it is estimated to increase by 11.10% in next year.
Analysts at 5 brokerage firms have issued recommendations for the OncoCyte Corporation (OCX)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.60. Out of those 5 Wall Street analysts, 2 recommended a “Buy” rating, while 3 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
On January 07, 2022, Stephens Initiated their recommendations, while on January 06, 2022, Piper Sandler Resumed their ratings for the stock with a price target of $3.10. Stock get a Buy rating from Needham on March 17, 2021.
Leave a Reply